BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: McLachlan SJ, Morris MR, Lucas MA, Fisco RA, Eakins MN, Fowler DR, Scheetz RB, Olukotun AY. Phase I clinical evaluation of a new iron oxide MR contrast agent. J Magn Reson Imaging. 1994;4:301-307. [PMID: 8061425 DOI: 10.1002/jmri.1880040313] [Cited by in Crossref: 148] [Cited by in F6Publishing: 139] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Bárcena C, Sra AK, Gao J. Applications of Magnetic Nanoparticles in Biomedicine. In: Liu JP, Fullerton E, Gutfleisch O, Sellmyer D, editors. Nanoscale Magnetic Materials and Applications. Boston: Springer US; 2009. pp. 591-626. [DOI: 10.1007/978-0-387-85600-1_20] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
2 Weissleder R, Bogdanov A, Neuwelt EA, Papisov M. Long-circulating iron oxides for MR imaging. Advanced Drug Delivery Reviews 1995;16:321-34. [DOI: 10.1016/0169-409x(95)00033-4] [Cited by in Crossref: 320] [Cited by in F6Publishing: 1] [Article Influence: 11.9] [Reference Citation Analysis]
3 Metz S, Bonaterra G, Rudelius M, Settles M, Rummeny EJ, Daldrup-Link HE. Capacity of human monocytes to phagocytose approved iron oxide MR contrast agents in vitro. Eur Radiol 2004;14:1851-8. [PMID: 15249981 DOI: 10.1007/s00330-004-2405-2] [Cited by in Crossref: 182] [Cited by in F6Publishing: 179] [Article Influence: 10.1] [Reference Citation Analysis]
4 Stillman AE, Wilke N, Jerosch-herold M. Use of an intravascular T1 contrast agent to improve MR cine myocardial-blood pool definition in man. J Magn Reson Imaging 1997;7:765-7. [DOI: 10.1002/jmri.1880070425] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 1.5] [Reference Citation Analysis]
5 Saini S, Sharma R, Baron R, Turner D, Ros P, Hahn P, Small W, Delange E, Stillman A, Edelman R, Runge V, Outwater E. Multicentre Dose-Ranging Study on the Efficacy of USPIO Ferumoxtran-10 for Liver MR Imaging. Clinical Radiology 2000;55:690-5. [DOI: 10.1053/crad.2000.0504] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
6 Bellin MF, Beigelman C, Precetti-Morel S. Iron oxide-enhanced MR lymphography: initial experience. Eur J Radiol 2000;34:257-64. [PMID: 10927166 DOI: 10.1016/s0720-048x(00)00204-7] [Cited by in Crossref: 73] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
7 Taylor AM, Panting JR, Keegan J, Gatehouse PD, Amin D, Jhooti P, Yang GZ, Mcgill S, Burman ED, Francis JM, Firmin DN, Pennell DJ. Safety and preliminary findings with the intravascular contrast agent NC100150 injection for MR coronary angiography. J Magn Reson Imaging 1999;9:220-7. [DOI: 10.1002/(sici)1522-2586(199902)9:2<220::aid-jmri11>3.0.co;2-a] [Cited by in Crossref: 97] [Cited by in F6Publishing: 9] [Article Influence: 4.2] [Reference Citation Analysis]
8 Wagenseil JE, Johansson LO, Lorenz CH. Characterization of t1 relaxation and blood-myocardial contrast enhancement of NC100150 injection in cardiac MRI. J Magn Reson Imaging 1999;10:784-9. [DOI: 10.1002/(sici)1522-2586(199911)10:5<784::aid-jmri24>3.0.co;2-a] [Cited by in Crossref: 37] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
9 Raynal I, Prigent P, Peyramaure S, Najid A, Rebuzzi C, Corot C. Macrophage endocytosis of superparamagnetic iron oxide nanoparticles: mechanisms and comparison of ferumoxides and ferumoxtran-10. Invest Radiol 2004;39:56-63. [PMID: 14701989 DOI: 10.1097/01.rli.0000101027.57021.28] [Cited by in Crossref: 302] [Cited by in F6Publishing: 281] [Article Influence: 16.8] [Reference Citation Analysis]
10 Saleh A, Schroeter M, Jonkmanns C, Hartung HP, Mödder U, Jander S. In vivo MRI of brain inflammation in human ischaemic stroke. Brain 2004;127:1670-7. [PMID: 15128622 DOI: 10.1093/brain/awh191] [Cited by in Crossref: 155] [Cited by in F6Publishing: 141] [Article Influence: 8.6] [Reference Citation Analysis]
11 Mergo PJ, Engelken JD, Helmberger T, Ros PR. MRI in focal liver disease: A comparison of small and ultra-small superparamagnetic iron oxide as hepatic contrast agents. J Magn Reson Imaging 1998;8:1073-8. [DOI: 10.1002/jmri.1880080511] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.0] [Reference Citation Analysis]
12 Nohynek GJ, Dufour EK. Nano-sized cosmetic formulations or solid nanoparticles in sunscreens: A risk to human health? Arch Toxicol 2012;86:1063-75. [DOI: 10.1007/s00204-012-0831-5] [Cited by in Crossref: 104] [Cited by in F6Publishing: 75] [Article Influence: 10.4] [Reference Citation Analysis]
13 Jung CW, Jacobs P. Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. Magn Reson Imaging. 1995;13:661-674. [PMID: 8569441 DOI: 10.1016/0730-725x(95)00024-b] [Cited by in Crossref: 509] [Cited by in F6Publishing: 101] [Article Influence: 19.6] [Reference Citation Analysis]
14 Langerak SE, Kunz P, de Roos A, Vliegen HW, van der Wall EE. Evaluation of coronary artery bypass grafts by magnetic resonance imaging. J Magn Reson Imaging 1999;10:434-41. [DOI: 10.1002/(sici)1522-2586(199909)10:3<434::aid-jmri27>3.0.co;2-g] [Cited by in Crossref: 13] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
15 Kroft LJ, Doornbos J, van der Geest RJ, van der Laarse A, van der Meulen H, de Roos A. Ultrasmall superparamagnetic particles of iron oxide (USPIO) MR imaging of infarcted myocardium in pigs. Magnetic Resonance Imaging 1998;16:755-63. [DOI: 10.1016/s0730-725x(98)00091-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
16 Bogdanov AA, Lewin M, Weissleder R. Approaches and agents for imaging the vascular system. Adv Drug Deliv Rev 1999;37:279-93. [PMID: 10837740 DOI: 10.1016/s0169-409x(98)00098-2] [Cited by in Crossref: 36] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
17 Azoulay R, Olivier P, Baud O, Verney C, Santus R, Robert P, Gressens P, Sebag G. USPIO (Ferumoxtran-10)-enhanced MRI to visualize reticuloendothelial system cells in neonatal rats: feasibility and biodistribution study. J Magn Reson Imaging 2008;28:1046-52. [PMID: 18821607 DOI: 10.1002/jmri.21510] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
18 Jun Y, Jang J, Cheon J. Magnetic Nanoparticle Assisted Molecular MR Imaging. In: Chan WCW, editor. Bio-Applications of Nanoparticles. New York: Springer; 2007. pp. 85-106. [DOI: 10.1007/978-0-387-76713-0_7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
19 Brillet PY, Gazeau F, Luciani A, Bessoud B, Cuénod CA, Siauve N, Pons JN, Poupon J, Clément O. Evaluation of tumoral enhancement by superparamagnetic iron oxide particles: comparative studies with ferumoxtran and anionic iron oxide nanoparticles. Eur Radiol 2005;15:1369-77. [PMID: 15726379 DOI: 10.1007/s00330-004-2586-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.2] [Reference Citation Analysis]
20 Hsiao YP, Shen CC, Huang CH, Lin YC, Jan TR. Iron oxide nanoparticles attenuate T helper 17 cell responses in vitro and in vivo. Int Immunopharmacol 2018;58:32-9. [PMID: 29549717 DOI: 10.1016/j.intimp.2018.03.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
21 Kuai R, Li D, Chen YE, Moon JJ, Schwendeman A. High-Density Lipoproteins: Nature's Multifunctional Nanoparticles. ACS Nano 2016;10:3015-41. [PMID: 26889958 DOI: 10.1021/acsnano.5b07522] [Cited by in Crossref: 152] [Cited by in F6Publishing: 142] [Article Influence: 25.3] [Reference Citation Analysis]
22 Tang TY, Howarth SP, Miller SR, Graves MJ, Patterson AJ, U-King-Im JM, Li ZY, Walsh SR, Brown AP, Kirkpatrick PJ. The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid disease. J Am Coll Cardiol. 2009;53:2039-2050. [PMID: 19477353 DOI: 10.1016/j.jacc.2009.03.018] [Cited by in Crossref: 284] [Cited by in F6Publishing: 232] [Article Influence: 21.8] [Reference Citation Analysis]
23 Maki JH, Chenevert TL, Prince MR. Contrast-enhanced MR angiography. Abdom Imaging 1998;23:469-84. [DOI: 10.1007/s002619900384] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 4.6] [Reference Citation Analysis]
24 Zaman RT, Kosuge H, Pratx G, Carpenter C, Xing L, McConnell MV. Fiber-optic system for dual-modality imaging of glucose probes 18F-FDG and 6-NBDG in atherosclerotic plaques. PLoS One 2014;9:e108108. [PMID: 25233472 DOI: 10.1371/journal.pone.0108108] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
25 Oude Engberink RD, van der Pol SM, Döpp EA, de Vries HE, Blezer EL. Comparison of SPIO and USPIO for in vitro labeling of human monocytes: MR detection and cell function. Radiology 2007;243:467-74. [PMID: 17456871 DOI: 10.1148/radiol.2432060120] [Cited by in Crossref: 96] [Cited by in F6Publishing: 94] [Article Influence: 6.4] [Reference Citation Analysis]
26 Anzai Y, Prince MR, Chenevert TL, Maki JH, London FLM, Mclachlan SJ. MR angiography with an ultrasmall superparamagnetic iron oxide blood pool agent. J Magn Reson Imaging 1997;7:209-14. [DOI: 10.1002/jmri.1880070132] [Cited by in Crossref: 124] [Cited by in F6Publishing: 111] [Article Influence: 5.0] [Reference Citation Analysis]
27 Chen IY, Wu JC. Cardiovascular molecular imaging: focus on clinical translation. Circulation 2011;123:425-43. [PMID: 21282520 DOI: 10.1161/CIRCULATIONAHA.109.916338] [Cited by in Crossref: 108] [Cited by in F6Publishing: 66] [Article Influence: 9.8] [Reference Citation Analysis]
28 Kim JI, Chun C, Kim B, Hong JM, Cho J, Lee SH, Song S. Thermosensitive/magnetic poly(organophosphazene) hydrogel as a long-term magnetic resonance contrast platform. Biomaterials 2012;33:218-24. [DOI: 10.1016/j.biomaterials.2011.09.033] [Cited by in Crossref: 75] [Cited by in F6Publishing: 60] [Article Influence: 7.5] [Reference Citation Analysis]
29 Farr TD, Seehafer JU, Nelles M, Hoehn M. Challenges towards MR imaging of the peripheral inflammatory response in the subacute and chronic stages of transient focal ischemia: CHALLENGES TOWARDS SUBACUTE STROKE INFLAMMATORY IMAGING. NMR Biomed 2011;24:35-45. [DOI: 10.1002/nbm.1553] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
30 Fischbein N, Anzai Y, Mukherji SK. Application of new imaging techniques for the evaluation of squamous cell carcinoma of the head and neck. Seminars in Ultrasound, CT and MRI 1999;20:187-212. [DOI: 10.1016/s0887-2171(99)90019-7] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
31 Kroft LJM, Doornbos J, van der Geest RJ, Benderbous S, de Roos A. Infarcted Myocardium in Pigs: MR Imaging Enhanced with Slow-Interstitial-Diffusion Gadolinium Compound P760. Radiology 1999;212:467-73. [DOI: 10.1148/radiology.212.2.r99au15467] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
32 Reichardt W, Hu-Lowe D, Torres D, Weissleder R, Bogdanov A Jr. Imaging of VEGF receptor kinase inhibitor-induced antiangiogenic effects in drug-resistant human adenocarcinoma model. Neoplasia 2005;7:847-53. [PMID: 16229807 DOI: 10.1593/neo.05139] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
33 Tsuchiya K, Nitta N, Sonoda A, Nitta-Seko A, Ohta S, Otani H, Takahashi M, Murata K, Murase K, Nohara S, Mukaisho K. Histological study of the biodynamics of iron oxide nanoparticles with different diameters. Int J Nanomedicine 2011;6:1587-94. [PMID: 21845049 DOI: 10.2147/IJN.S22189] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
34 Vonken EJ, Korosoglou G, Yu J, Schär M, Weissleder R, Stuber M. On the dual contrast enhancement mechanism in frequency-selective inversion-recovery magnetic resonance angiography (IRON-MRA). Magn Reson Med 2009;62:314-24. [PMID: 19526511 DOI: 10.1002/mrm.22027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
35 Lim SW, Kim HW, Jun HY, Park SH, Yoon KH, Kim HS, Jon S, Yu MK, Juhng SK. TCL-SPION-enhanced MRI for the detection of lymph node metastasis in murine experimental model. Acad Radiol 2011;18:504-11. [PMID: 21216633 DOI: 10.1016/j.acra.2010.10.017] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
36 Allkemper T, Bremer C, Matuszewski L, Ebert W, Reimer P. Contrast-enhanced blood-pool MR angiography with optimized iron oxides: effect of size and dose on vascular contrast enhancement in rabbits. Radiology 2002;223:432-8. [PMID: 11997549 DOI: 10.1148/radiol.2232010241] [Cited by in Crossref: 98] [Cited by in F6Publishing: 94] [Article Influence: 4.9] [Reference Citation Analysis]
37 Mccauley TR, Rifkin MD, Ledet CA. Pelvic lymph node visualization with MR imaging using local administration of ultra-small superparamagnetic iron oxide contrast. J Magn Reson Imaging 2002;15:492-7. [DOI: 10.1002/jmri.10089] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
38 Gunn AJ, Seethamraju RT, Hedgire S, Elmi A, Daniels GH, Harisinghani MG. Imaging Behavior of the Normal Adrenal on Ferumoxytol-Enhanced MRI: Preliminary Findings. American Journal of Roentgenology 2013;201:117-21. [DOI: 10.2214/ajr.12.9357] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
39 Prodi L, Rampazzo E, Rastrelli F, Speghini A, Zaccheroni N. Imaging agents based on lanthanide doped nanoparticles. Chem Soc Rev 2015;44:4922-52. [DOI: 10.1039/c4cs00394b] [Cited by in Crossref: 136] [Cited by in F6Publishing: 19] [Article Influence: 19.4] [Reference Citation Analysis]
40 Jacques V, Desreux JF. New Classes of MRI Contrast Agents. In: Krause W, editor. Contrast Agents I. Berlin: Springer Berlin Heidelberg; 2002. pp. 123-64. [DOI: 10.1007/3-540-45733-x_5] [Cited by in Crossref: 119] [Article Influence: 6.0] [Reference Citation Analysis]
41 Nishimura H, Tanigawa N, Hiramatsu M, Tatsumi Y, Matsuki M, Narabayashi I. Preoperative esophageal cancer staging: magnetic resonance imaging of lymph node with ferumoxtran-10, an ultrasmall superparamagnetic iron oxide. J Am Coll Surg 2006;202:604-11. [PMID: 16571430 DOI: 10.1016/j.jamcollsurg.2005.12.004] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 2.8] [Reference Citation Analysis]
42 Low RN. Contrast agents for MR imaging of the liver. J Magn Reson Imaging 1997;7:56-67. [DOI: 10.1002/jmri.1880070109] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 1.4] [Reference Citation Analysis]
43 Li C, Harisinghani MG, Lin W, Braschi M, Hahn PF, Mueller PR. Enhancement Characteristics of Ultrasmall Superparamagnetic Iron Oxide Particle Within the Prostate Gland in Patients With Primary Prostate Cancer: . Journal of Computer Assisted Tomography 2008;32:523-8. [DOI: 10.1097/rct.0b013e318136e194] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
44 Reichert DE, Lewis JS, Anderson CJ. Metal complexes as diagnostic tools. Coordination Chemistry Reviews 1999;184:3-66. [DOI: 10.1016/s0010-8545(98)00207-0] [Cited by in Crossref: 210] [Article Influence: 9.1] [Reference Citation Analysis]
45 Harisinghani MG, Saini S, Weissleder R, Rubin D, deLange E, Harms S, Weinreb J, Small W, Sukerkar A, Brown JJ, Zelch J, Lucas M, Morris M, Hahn PF. Splenic Imaging with Ultrasmall Superparamagnetic Iron Oxide Ferumoxtran-10 (AMI-7227): Preliminary Observations: . Journal of Computer Assisted Tomography 2001;25:770-6. [DOI: 10.1097/00004728-200109000-00017] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
46 Kolishetti N, Alexis F, Pridgen EM, Farokhzad OC. Biodistribution and Pharmacokinetics of Nanoprobes. In: Chen X, editor. Nanoplatform-Based Molecular Imaging. Hoboken: John Wiley & Sons, Inc.; 2011. pp. 75-104. [DOI: 10.1002/9780470767047.ch4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
47 Mitchell DG. MR imaging contrast agents — what's in a name? J Magn Reson Imaging 1997;7:1-4. [DOI: 10.1002/jmri.1880070102] [Cited by in Crossref: 97] [Cited by in F6Publishing: 72] [Article Influence: 3.9] [Reference Citation Analysis]
48 Yancy AD, Olzinski AR, Hu TC, Lenhard SC, Aravindhan K, Gruver SM, Jacobs PM, Willette RN, Jucker BM. Differential uptake of ferumoxtran-10 and ferumoxytol, ultrasmall superparamagnetic iron oxide contrast agents in rabbit: critical determinants of atherosclerotic plaque labeling. J Magn Reson Imaging 2005;21:432-42. [PMID: 15779033 DOI: 10.1002/jmri.20283] [Cited by in Crossref: 86] [Cited by in F6Publishing: 68] [Article Influence: 5.1] [Reference Citation Analysis]
49 Laurent S, Forge D, Port M, Roch A, Robic C, Vander Elst L, Muller RN. Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chem Rev 2008;108:2064-110. [PMID: 18543879 DOI: 10.1021/cr068445e] [Cited by in Crossref: 4625] [Cited by in F6Publishing: 3554] [Article Influence: 330.4] [Reference Citation Analysis]
50 Enochs WS, Harsh G, Hochberg F, Weissleder R. Improved delineation of human brain tumors on MR images using a long-circulating, superparamagnetic iron oxide agent. J Magn Reson Imaging 1999;9:228-32. [DOI: 10.1002/(sici)1522-2586(199902)9:2<228::aid-jmri12>3.0.co;2-k] [Cited by in Crossref: 167] [Cited by in F6Publishing: 43] [Article Influence: 7.3] [Reference Citation Analysis]
51 Shen CC, Liang HJ, Wang CC, Liao MH, Jan TR. Iron oxide nanoparticles suppressed T helper 1 cell-mediated immunity in a murine model of delayed-type hypersensitivity. Int J Nanomedicine 2012;7:2729-37. [PMID: 22701318 DOI: 10.2147/IJN.S31054] [Cited by in Crossref: 8] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
52 Weinmann HJ, Ebert W, Misselwitz B, Schmitt-Willich H. Tissue-specific MR contrast agents. Eur J Radiol 2003;46:33-44. [PMID: 12648800 DOI: 10.1016/s0720-048x(02)00332-7] [Cited by in Crossref: 192] [Cited by in F6Publishing: 31] [Article Influence: 10.1] [Reference Citation Analysis]
53 Wagner M, Wagner S, Schnorr J, Schellenberger E, Kivelitz D, Krug L, Dewey M, Laule M, Hamm B, Taupitz M. Coronary MR angiography using citrate-coated very small superparamagnetic iron oxide particles as blood-pool contrast agent: initial experience in humans. J Magn Reson Imaging. 2011;34:816-823. [PMID: 21769977 DOI: 10.1002/jmri.22683] [Cited by in Crossref: 40] [Cited by in F6Publishing: 46] [Article Influence: 3.6] [Reference Citation Analysis]
54 Zare T, Lotfi M, Heli H, Azarpira N, Mehdizadeh AR, Sattarahmady N, Abdollah-dizavandi MR, Heidari M. Synthesis, characterization, in vitro and in vivo studies of dextrin-coated zinc-iron ferrite nanoparticles (Zn0.5Fe0.5Fe2O4) as contrast agent in MRI. Appl Phys A 2015;120:1189-96. [DOI: 10.1007/s00339-015-9302-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
55 Anzai Y, Piccoli CW, Outwater EK, Stanford W, Bluemke DA, Nurenberg P, Saini S, Maravilla KR, Feldman DE, Schmiedl UP, Brunberg JA, Francis IR, Harms SE, Som PM, Tempany CM. Evaluation of Neck and Body Metastases to Nodes with Ferumoxtran 10–enhanced MR Imaging: Phase III Safety and Efficacy Study. Radiology 2003;228:777-88. [DOI: 10.1148/radiol.2283020872] [Cited by in Crossref: 216] [Cited by in F6Publishing: 178] [Article Influence: 11.4] [Reference Citation Analysis]
56 Mclachlan SJ, Morris M, Lucas MA, Baum LM. Preliminary clinical experience with AMI 227. Academic Radiology 1996;3:S295-6. [DOI: 10.1016/s1076-6332(96)80561-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
57 Hartman KB, Wilson LJ, Rosenblum MG. Detecting and treating cancer with nanotechnology. Mol Diagn Ther 2008;12:1-14. [PMID: 18288878 DOI: 10.1007/BF03256264] [Cited by in Crossref: 71] [Cited by in F6Publishing: 21] [Article Influence: 5.1] [Reference Citation Analysis]
58 Nguyen BC, Stanford W, Thompson BH, Rossi NP, Kernstine KH, Kern JA, Robinson RA, Amorosa JK, Mammone JF, Outwater EK. Multicenter clinical trial of ultrasmall superparamagnetic iron oxide in the evaluation of mediastinal lymph nodes in patients with primary lung carcinoma. J Magn Reson Imaging 1999;10:468-73. [DOI: 10.1002/(sici)1522-2586(199909)10:3<468::aid-jmri31>3.0.co;2-i] [Cited by in Crossref: 61] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
59 Shanehsazzadeh S, Gruettner C, Lahooti A, Mahmoudi M, Allen BJ, Ghavami M, Daha FJ, Oghabian MA. Monoclonal antibody conjugated magnetic nanoparticles could target MUC-1-positive cells in vitro but not in vivo. Contrast Media Mol Imaging 2015;10:225-36. [PMID: 25327822 DOI: 10.1002/cmmi.1627] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 3.5] [Reference Citation Analysis]
60 Zaman RT, Kosuge H, Carpenter C, Sun C, McConnell MV, Xing L. Scintillating balloon-enabled fiber-optic system for radionuclide imaging of atherosclerotic plaques. J Nucl Med 2015;56:771-7. [PMID: 25858046 DOI: 10.2967/jnumed.114.153239] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
61 Park J, Cho W, Park HJ, Cha KH, Ha DC, Choi YW, Lee HY, Cho SH, Hwang SJ. Biodistribution of newly synthesized PHEA-based polymer-coated SPION in Sprague Dawley rats as magnetic resonance contrast agent. Int J Nanomedicine 2013;8:4077-89. [PMID: 24204138 DOI: 10.2147/IJN.S51684] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
62 Schnorr J, Taupitz M, Wagner S, Pilgrimm H, Hansel J, Hamm B. Age-related blood half-life of particulate contrast material: experimental results with a USPIO in rats. J Magn Reson Imaging 2000;12:740-4. [PMID: 11050644 DOI: 10.1002/1522-2586(200011)12:5<740::aid-jmri11>3.0.co;2-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
63 Min Y, Caster JM, Eblan MJ, Wang AZ. Clinical Translation of Nanomedicine. Chem Rev 2015;115:11147-90. [PMID: 26088284 DOI: 10.1021/acs.chemrev.5b00116] [Cited by in Crossref: 424] [Cited by in F6Publishing: 377] [Article Influence: 60.6] [Reference Citation Analysis]
64 Aghighi M, Golovko D, Ansari C, Marina NM, Pisani L, Kurlander L, Klenk C, Bhaumik S, Wendland M, Daldrup-Link HE. Imaging Tumor Necrosis with Ferumoxytol. PLoS One 2015;10:e0142665. [PMID: 26569397 DOI: 10.1371/journal.pone.0142665] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
65 Mahmoudi M, Simchi A, Milani AS, Stroeve P. Cell toxicity of superparamagnetic iron oxide nanoparticles. J Colloid Interface Sci 2009;336:510-8. [PMID: 19476952 DOI: 10.1016/j.jcis.2009.04.046] [Cited by in Crossref: 239] [Cited by in F6Publishing: 216] [Article Influence: 18.4] [Reference Citation Analysis]
66 Chan N, Laprise-Pelletier M, Chevallier P, Bianchi A, Fortin MA, Oh JK. Multidentate block-copolymer-stabilized ultrasmall superparamagnetic iron oxide nanoparticles with enhanced colloidal stability for magnetic resonance imaging. Biomacromolecules 2014;15:2146-56. [PMID: 24785001 DOI: 10.1021/bm500311k] [Cited by in Crossref: 44] [Cited by in F6Publishing: 33] [Article Influence: 5.5] [Reference Citation Analysis]
67 Wadghiri YZ, Li J, Wang J, Hoang DM, Sun Y, Xu H, Tsui W, Li Y, Boutajangout A, Wang A, de Leon M, Wisniewski T. Detection of amyloid plaques targeted by bifunctional USPIO in Alzheimer's disease transgenic mice using magnetic resonance microimaging. PLoS One 2013;8:e57097. [PMID: 23468919 DOI: 10.1371/journal.pone.0057097] [Cited by in Crossref: 68] [Cited by in F6Publishing: 59] [Article Influence: 7.6] [Reference Citation Analysis]
68 Perez-Balderas F, van Kasteren SI, Aljabali AA, Wals K, Serres S, Jefferson A, Sarmiento Soto M, Khrapitchev AA, Larkin JR, Bristow C, Lee SS, Bort G, De Simone F, Campbell SJ, Choudhury RP, Anthony DC, Sibson NR, Davis BG. Covalent assembly of nanoparticles as a peptidase-degradable platform for molecular MRI. Nat Commun 2017;8:14254. [PMID: 28198362 DOI: 10.1038/ncomms14254] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
69 Memarsadeghi M, Riedl CC, Kaneider A, Galid A, Rudas M, Matzek W, Helbich TH. Axillary lymph node metastases in patients with breast carcinomas: assessment with nonenhanced versus uspio-enhanced MR imaging. Radiology 2006;241:367-77. [PMID: 17057065 DOI: 10.1148/radiol.2412050693] [Cited by in Crossref: 78] [Cited by in F6Publishing: 69] [Article Influence: 4.9] [Reference Citation Analysis]
70 Vu-quang H, Yoo M, Jeong H, Lee H, Muthiah M, Rhee JH, Lee J, Cho C, Jeong YY, Park I. Targeted delivery of mannan-coated superparamagnetic iron oxide nanoparticles to antigen-presenting cells for magnetic resonance-based diagnosis of metastatic lymph nodes in vivo. Acta Biomaterialia 2011;7:3935-45. [DOI: 10.1016/j.actbio.2011.06.044] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
71 Reimer P, Allkemper T, Matuszewski L, Balzer T. Contrast-enhanced 3D-MRA of the upper abdomen with a bolus-injectable SPIO (SH U 555 A). J Magn Reson Imaging 1999;10:65-71. [DOI: 10.1002/(sici)1522-2586(199907)10:1<65::aid-jmri9>3.0.co;2-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
72 Anzai Y, Prince MR. Iron oxide-enhanced MR lymphography: The evaluation of cervical lymph node metastases in head and neck cancer. J Magn Reson Imaging 1997;7:75-81. [DOI: 10.1002/jmri.1880070111] [Cited by in Crossref: 79] [Cited by in F6Publishing: 61] [Article Influence: 3.2] [Reference Citation Analysis]
73 Tang TY, Patterson AJ, Miller SR, Graves MJ, Howarth SPS, U-king-im JM, Li ZY, Sadat U, Young VE, Walsh SR, Boyle JR, Gaunt ME, Gillard JH. Temporal dependence of in vivo USPIO-enhanced MRI signal changes in human carotid atheromatous plaques. Neuroradiology 2009;51:457-65. [DOI: 10.1007/s00234-009-0523-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
74 Kim JI, Lee BS, Chun C, Cho JK, Kim SY, Song SC. Long-term theranostic hydrogel system for solid tumors. Biomaterials 2012;33:2251-9. [PMID: 22189146 DOI: 10.1016/j.biomaterials.2011.11.083] [Cited by in Crossref: 54] [Cited by in F6Publishing: 43] [Article Influence: 4.9] [Reference Citation Analysis]
75 Adzamli K, Dorshow RB, Hynes MR, Li D, Nosco DL, Adams MD. Preliminary evaluation of a polyethyleneglycol-stabilized manganese-substituted hydroxylapatite as an intravascular contrast agent for MR angiography. J Magn Reson Imaging 1997;7:204-8. [PMID: 9039616 DOI: 10.1002/jmri.1880070131] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
76 Bonnard T, Serfaty J, Journé C, Ho Tin Noe B, Arnaud D, Louedec L, Derkaoui SM, Letourneur D, Chauvierre C, Le Visage C. Leukocyte mimetic polysaccharide microparticles tracked in vivo on activated endothelium and in abdominal aortic aneurysm. Acta Biomaterialia 2014;10:3535-45. [DOI: 10.1016/j.actbio.2014.04.015] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
77 Pai AB, Garba AO. Ferumoxytol: a silver lining in the treatment of anemia of chronic kidney disease or another dark cloud? J Blood Med. 2012;3:77-85. [PMID: 22973119 DOI: 10.2147/jbm.s29204] [Cited by in Crossref: 5] [Cited by in F6Publishing: 20] [Article Influence: 0.5] [Reference Citation Analysis]
78 Wang AZ, Gu FX, Farokhzad OC. Nanoparticles for Cancer Diagnosis and Therapy. In: Webster TJ, editor. Safety of Nanoparticles. New York: Springer; 2009. pp. 209-35. [DOI: 10.1007/978-0-387-78608-7_10] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
79 Tombach B, Reimer P, Bremer C, Allkemper T, Engelhardt M, Mahler M, Ebert W, Heindel W. First-pass and equilibrium-MRA of the aortoiliac region with a superparamagnetic iron oxide blood pool MR contrast agent (SH U 555 C): results of a human pilot study. NMR Biomed 2004;17:500-6. [DOI: 10.1002/nbm.906] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 2.9] [Reference Citation Analysis]
80 Li W, Tutton S, Vu AT, Pierchala L, Li BS, Lewis JM, Prasad PV, Edelman RR. First-pass contrast-enhanced magnetic resonance angiography in humans using ferumoxytol, a novel ultrasmall superparamagnetic iron oxide (USPIO)-based blood pool agent. J Magn Reson Imaging 2005;21:46-52. [DOI: 10.1002/jmri.20235] [Cited by in Crossref: 168] [Cited by in F6Publishing: 146] [Article Influence: 9.3] [Reference Citation Analysis]
81 Hifumi H, Yamaoka S, Tanimoto A, Citterio D, Suzuki K. Gadolinium-based hybrid nanoparticles as a positive MR contrast agent. J Am Chem Soc 2006;128:15090-1. [PMID: 17117851 DOI: 10.1021/ja066442d] [Cited by in Crossref: 204] [Cited by in F6Publishing: 170] [Article Influence: 13.6] [Reference Citation Analysis]
82 Murillo TP, Sandquist C, Jacobs PM, Nesbit G, Manninger S, Neuwelt EA. Imaging brain tumors with ferumoxtran-10, a nanoparticle magnetic resonance contrast agent. Therapy 2005;2:871-82. [DOI: 10.2217/14750708.2.6.871] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
83 Cheng WZ, Zeng MS, Yan FH, Rao SX, Shen JZ, Chen CZ, Zhang SJ, Shi WB. Ferucarbotran versus Gd-DTPA-enhanced MR imaging in the detection of focal hepatic lesions. World J Gastroenterol 2007; 13(36): 4891-4896 [PMID: 17828821 DOI: 10.3748/wjg.v13.i36.4891] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
84 Zaman RT, Yousefi S, Long SR, Saito T, Mandella M, Qiu Z, Chen R, Contag CH, Gambhir SS, Chin FT, Khuri-Yakub BT, McConnell MV, Shung KK, Xing L. A Dual-Modality Hybrid Imaging System Harnesses Radioluminescence and Sound to Reveal Molecular Pathology of Atherosclerotic Plaques. Sci Rep 2018;8:8992. [PMID: 29895966 DOI: 10.1038/s41598-018-26696-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
85 Bourrinet P, Bengele HH, Bonnemain B, Dencausse A, Idee JM, Jacobs PM, Lewis JM. Preclinical safety and pharmacokinetic profile of ferumoxtran-10, an ultrasmall superparamagnetic iron oxide magnetic resonance contrast agent. Invest Radiol 2006;41:313-24. [PMID: 16481915 DOI: 10.1097/01.rli.0000197669.80475.dd] [Cited by in Crossref: 219] [Cited by in F6Publishing: 199] [Article Influence: 13.7] [Reference Citation Analysis]
86 Imam K, Bluemke DA. MR IMAGING IN THE EVALUATION OF HEPATIC METASTASES. Magnetic Resonance Imaging Clinics of North America 2000;8:741-56. [DOI: 10.1016/s1064-9689(21)00641-3] [Cited by in Crossref: 15] [Article Influence: 0.7] [Reference Citation Analysis]
87 Taupitz M, Schnorr J, Wagner S, Abramjuk C, Pilgrimm H, Kivelitz D, Schink T, Hansel J, Laub G, Hünigen H, Hamm B. Coronary MR Angiography: Experimental Results with a Monomer-stabilized Blood Pool Contrast Medium. Radiology 2002;222:120-6. [DOI: 10.1148/radiol.2221001452] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 1.7] [Reference Citation Analysis]
88 Anzai Y. Superparamagnetic Iron Oxide Nanoparticles: Nodal Metastases and Beyond. Topics in Magnetic Resonance Imaging 2004;15:103-11. [DOI: 10.1097/01.rmr.0000130602.65243.87] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
89 Stets C, Brandt S, Wallis F, Buchmann J, Gilbert F, Heywang-köbrunner SH. Axillary lymph node metastases: A statistical analysis of various parameters in MRI with USPIO: Axillary Lymph Node Metastases. J Magn Reson Imaging 2002;16:60-8. [DOI: 10.1002/jmri.10134] [Cited by in Crossref: 53] [Cited by in F6Publishing: 43] [Article Influence: 2.7] [Reference Citation Analysis]
90 Simon GH, von Vopelius-Feldt J, Fu Y, Schlegel J, Pinotek G, Wendland MF, Chen MH, Daldrup-Link HE. Ultrasmall supraparamagnetic iron oxide-enhanced magnetic resonance imaging of antigen-induced arthritis: a comparative study between SHU 555 C, ferumoxtran-10, and ferumoxytol. Invest Radiol 2006;41:45-51. [PMID: 16355039 DOI: 10.1097/01.rli.0000191367.61306.83] [Cited by in Crossref: 82] [Cited by in F6Publishing: 74] [Article Influence: 5.1] [Reference Citation Analysis]
91 Harisinghani MG, Saini S, Hahn PF, Weissleder R, Mueller PR. MR imaging of lymph nodes in patients with primary abdominal and pelvic malignancies using ultrasmall superparamagnetic iron oxide (Combidex). Academic Radiology 1998;5:S167-9. [DOI: 10.1016/s1076-6332(98)80095-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
92 Trivedi RA, U-King-Im JM, Graves MJ, Cross JJ, Horsley J, Goddard MJ, Skepper JN, Quartey G, Warburton E, Joubert I. In vivo detection of macrophages in human carotid atheroma: temporal dependence of ultrasmall superparamagnetic particles of iron oxide-enhanced MRI. Stroke. 2004;35:1631-1635. [PMID: 15166394 DOI: 10.1161/01.str.0000131268.50418.b7] [Cited by in Crossref: 234] [Cited by in F6Publishing: 89] [Article Influence: 13.0] [Reference Citation Analysis]
93 Heesakkers RA, Hövels AM, Jager GJ, van den Bosch HC, Witjes JA, Raat HP, Severens JL, Adang EM, van der Kaa CH, Fütterer JJ, Barentsz J. MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncol 2008;9:850-6. [PMID: 18708295 DOI: 10.1016/S1470-2045(08)70203-1] [Cited by in Crossref: 221] [Cited by in F6Publishing: 72] [Article Influence: 15.8] [Reference Citation Analysis]
94 Lim E, Jang E, Kim B, Choi J, Lee K, Suh J, Huh Y, Haam S. Dextran-coated magnetic nanoclusters as highly sensitive contrast agents for magnetic resonance imaging of inflammatory macrophages. J Mater Chem 2011;21:12473. [DOI: 10.1039/c1jm10764j] [Cited by in Crossref: 27] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
95 Curvo-semedo L, Diniz M, Miguéis J, Julião M, Martins P, Pinto A, Caseiro-alves F. USPIO-enhanced magnetic resonance imaging for nodal staging in patients with head and neck cancer. J Magn Reson Imaging 2006;24:123-31. [DOI: 10.1002/jmri.20602] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
96 Schmitz SA, Albrecht T, Wolf K. MR Angiography with Superparamagnetic Iron Oxide: Feasibility Study. Radiology 1999;213:603-7. [DOI: 10.1148/radiology.213.2.r99oc24603] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
97 Fernández T, Martínez-serrano A, Cussó L, Desco M, Ramos-gómez M. Functionalization and Characterization of Magnetic Nanoparticles for the Detection of Ferritin Accumulation in Alzheimer’s Disease. ACS Chem Neurosci 2018;9:912-24. [DOI: 10.1021/acschemneuro.7b00260] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
98 Schmitz SA, Taupitz M, Wagner S, Wolf K, Beyersdorff D, Hamm B. Magnetic resonance imaging of atherosclerotic plaques using superparamagnetic iron oxide particles. J Magn Reson Imaging 2001;14:355-61. [DOI: 10.1002/jmri.1194] [Cited by in Crossref: 156] [Cited by in F6Publishing: 129] [Article Influence: 7.4] [Reference Citation Analysis]
99 Pai AB, Nielsen JC, Kausz A, Miller P, Owen JS. Plasma pharmacokinetics of two consecutive doses of ferumoxytol in healthy subjects. Clin Pharmacol Ther 2010;88:237-42. [PMID: 20592725 DOI: 10.1038/clpt.2010.80] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
100 Chetwynd AJ, Guggenheim EJ, Briffa SM, Thorn JA, Lynch I, Valsami-Jones E. Current Application of Capillary Electrophoresis in Nanomaterial Characterisation and Its Potential to Characterise the Protein and Small Molecule Corona. Nanomaterials (Basel) 2018;8:E99. [PMID: 29439415 DOI: 10.3390/nano8020099] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
101 Usman A, Sadat U, Patterson AJ, Tang TY, Varty K, Boyle JR, Armon MP, Hayes PD, Graves MJ, Gillard JH. Use of ultrasmall superparamagnetic iron oxide particles for imaging carotid atherosclerosis. Nanomedicine (Lond) 2015;10:3077-87. [PMID: 26420349 DOI: 10.2217/nnm.15.136] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
102 Shah GV, Fischbein NJ, Patel R, Mukherji SK. Newer MR imaging techniques for head and neck. Magnetic Resonance Imaging Clinics of North America 2003;11:449-69. [DOI: 10.1016/s1064-9689(03)00069-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
103 Alison M, Azoulay R, Chalard F, Gressens P, Sebag G. In vivo assessment of experimental neonatal excitotoxic brain lesion with USPIO-enhanced MR imaging. Eur Radiol 2010;20:2204-12. [PMID: 20393713 DOI: 10.1007/s00330-010-1793-8] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
104 Ye Y, Bogaert J. Cell therapy in myocardial infarction: emphasis on the role of MRI. Eur Radiol 2008;18:548-69. [DOI: 10.1007/s00330-007-0777-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
105 Noguchi M, Tsugawa K, Bando E, Kawahara F, Miwa K, Yokoyama K, Nakajima K, Tonami N. Sentinel lymphadenectomy in breast cancer: identification of sentinel lymph node and detection of metastases. Breast Cancer Res Treat 1999;53:97-104. [DOI: 10.1023/a:1006118827167] [Cited by in Crossref: 26] [Cited by in F6Publishing: 2] [Article Influence: 1.1] [Reference Citation Analysis]
106 Jung CW. Surface properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. Magn Reson Imaging 1995;13:675-91. [PMID: 8569442 DOI: 10.1016/0730-725x(95)00023-a] [Cited by in Crossref: 176] [Cited by in F6Publishing: 51] [Article Influence: 6.8] [Reference Citation Analysis]
107 Chan N, Li P, Oh JK. Chain Length Effect of the Multidentate Block Copolymer Strategy to Stabilize Ultrasmall Fe 3 O 4 Nanoparticles. ChemPlusChem 2014;79:1342-51. [DOI: 10.1002/cplu.201402112] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
108 Moudgil R, Dick AJ. Regenerative Cell Imaging in Cardiac Repair. Canadian Journal of Cardiology 2014;30:1323-34. [DOI: 10.1016/j.cjca.2014.08.028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
109 Taupitz M, Wagner S, Schnorr J, Kravec I, Pilgrimm H, Bergmann-fritsch H, Hamm B. Phase I Clinical Evaluation of Citrate-coated Monocrystalline Very Small Superparamagnetic Iron Oxide Particles as a New Contrast Medium for Magnetic Resonance Imaging. Investigative Radiology 2004;39:394-405. [DOI: 10.1097/01.rli.0000129472.45832.b0] [Cited by in Crossref: 115] [Cited by in F6Publishing: 101] [Article Influence: 6.4] [Reference Citation Analysis]
110 Sun W, Hu Q, Ji W, Wright G, Gu Z. Leveraging Physiology for Precision Drug Delivery. Physiological Reviews 2017;97:189-225. [DOI: 10.1152/physrev.00015.2016] [Cited by in Crossref: 92] [Cited by in F6Publishing: 52] [Article Influence: 18.4] [Reference Citation Analysis]
111 De M, Chou SS, Joshi HM, Dravid VP. Hybrid magnetic nanostructures (MNS) for magnetic resonance imaging applications. Adv Drug Deliv Rev 2011;63:1282-99. [PMID: 21851844 DOI: 10.1016/j.addr.2011.07.001] [Cited by in Crossref: 53] [Cited by in F6Publishing: 42] [Article Influence: 4.8] [Reference Citation Analysis]
112 Schnorr J, Wagner S, Abramjuk C, Wojner I, Schink T, Kroencke TJ, Schellenberger E, Hamm B, Pilgrimm H, Taupitz M. Comparison of the Iron Oxide-Based Blood-Pool Contrast Medium VSOP-C184 With Gadopentetate Dimeglumine for First-Pass Magnetic Resonance Angiography of the Aorta and Renal Arteries in Pigs. Investigative Radiology 2004;39:546-53. [DOI: 10.1097/01.rli.0000133944.30119.cc] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 2.1] [Reference Citation Analysis]
113 Yu C, Zhao J, Guo Y, Lu C, Ma X, Gu Z. A novel method to prepare water-dispersible magnetic nanoparticles and their biomedical applications: magnetic capture probe and specific cellular uptake. J Biomed Mater Res A 2008;87:364-72. [PMID: 18181113 DOI: 10.1002/jbm.a.31786] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
114 Malyutin AG, Cheng H, Sanchez-felix OR, Carlson K, Stein BD, Konarev PV, Svergun DI, Dragnea B, Bronstein LM. Coat Protein-Dependent Behavior of Poly(ethylene glycol) Tails in Iron Oxide Core Virus-like Nanoparticles. ACS Appl Mater Interfaces 2015;7:12089-98. [DOI: 10.1021/acsami.5b02278] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
115 Bremerich J, Roberts TP, Wendland MF, Wyttenbach R, Arheden H, Reddy GP, Shafaghi N, Higgins CB, Saeed M. Three-dimensional MR imaging of pulmonary vessels and parenchyma with NC100150 injection (Clariscan?). J Magn Reson Imaging 2000;11:622-8. [DOI: 10.1002/1522-2586(200006)11:6<622::aid-jmri8>3.0.co;2-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
116 Zaman RT, Yousefi S, Chibana H, Ikeno F, Long SR, Gambhir SS, Chin FT, McConnell MV, Xing L, Yeung A. In Vivo Translation of the CIRPI System: Revealing Molecular Pathology of Rabbit Aortic Atherosclerotic Plaques. J Nucl Med 2019;60:1308-16. [PMID: 30737298 DOI: 10.2967/jnumed.118.222471] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
117 Patterson AJ, Tang TY, Graves MJ, Müller KH, Gillard JH. In vivo carotid plaque MRI using quantitative T2* measurements with ultrasmall superparamagnetic iron oxide particles: a dose-response study to statin therapy. NMR Biomed 2011;24:89-95. [PMID: 21259368 DOI: 10.1002/nbm.1560] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
118 Loubeyre P, De Jaegere T, Bosmans H, Miao Y, Ni Y, Landuyt W, Marchal G. Comparison of iron oxide particles (AMI 227) with a gadolinium complex (Gd-DOTA) in dynamic susceptibility contrast MR imagings (FLASH and EPI) for both phantom and rat brain at 1.5 tesla. J Magn Reson Imaging 1999;9:447-53. [DOI: 10.1002/(sici)1522-2586(199903)9:3<447::aid-jmri13>3.0.co;2-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
119 Wei H, Tan T, Cheng L, Liu J, Song H, Li L, Zhang K. MRI tracing of ultrasmall superparamagnetic iron oxide nanoparticle‑labeled endothelial progenitor cells for repairing atherosclerotic vessels in rabbits. Mol Med Rep 2020;22:3327-37. [PMID: 32945451 DOI: 10.3892/mmr.2020.11431] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
120 Petersein J, Saini S, Weissleder R. LIVER II: IRON OXIDE-BASED RETICULOENDOTHELIAL CONTRAST AGENTS FOR MR IMAGING. Magnetic Resonance Imaging Clinics of North America 1996;4:53-60. [DOI: 10.1016/s1064-9689(21)00553-5] [Cited by in Crossref: 18] [Article Influence: 0.7] [Reference Citation Analysis]
121 Svensson J, Leander P, Maki JH, Stahlberg F, Olsson LE. Separation of arteries and veins using flow-induced phase effects in contrast-enhanced MRA of the lower extremities. Magnetic Resonance Imaging 2002;20:49-57. [DOI: 10.1016/s0730-725x(02)00479-4] [Cited by in Crossref: 9] [Article Influence: 0.5] [Reference Citation Analysis]
122 Landry R, Jacobs PM, Davis R, Shenouda M, Bolton WK. Pharmacokinetic study of ferumoxytol: a new iron replacement therapy in normal subjects and hemodialysis patients. Am J Nephrol 2005;25:400-10. [PMID: 16088081 DOI: 10.1159/000087212] [Cited by in Crossref: 72] [Cited by in F6Publishing: 73] [Article Influence: 4.2] [Reference Citation Analysis]
123 Wagner S, Schnorr J, Ludwig A, Stangl V, Ebert M, Hamm B, Taupitz M. Contrast-enhanced MR imaging of atherosclerosis using citrate-coated superparamagnetic iron oxide nanoparticles: calcifying microvesicles as imaging target for plaque characterization. Int J Nanomedicine 2013;8:767-79. [PMID: 23450179 DOI: 10.2147/IJN.S38702] [Cited by in Crossref: 4] [Cited by in F6Publishing: 13] [Article Influence: 0.4] [Reference Citation Analysis]
124 Schütz G, Lohrke J, Pietsch H. Lymph node staging using dedicated magnetic resonance contrast agents--the accumulation mechanism revisited. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2015;7:238-49. [PMID: 25266498 DOI: 10.1002/wnan.1290] [Reference Citation Analysis]
125 Saini S, Edelman RR, Li W, Petersein J, Hahn PF. Clinical evaluation of ultrasmall superparamagnetic iron oxide particles for liver imaging. Academic Radiology 1996;3:S409-12. [DOI: 10.1016/s1076-6332(96)80600-3] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
126 Gibby WA. MRI Contrast Agents. In: Zimmerman RA, Gibby WA, Carmody RF, editors. Neuroimaging. New York: Springer; 2000. pp. 313-64. [DOI: 10.1007/978-1-4612-1152-5_10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
127 Liu L, Liu L, Li Y, Huang X, Gu D, Wei B, Su D, Jin G. Ultrasmall superparamagnetic nanoparticles targeting E-selectin: synthesis and effects in mice in vitro and in vivo. Int J Nanomedicine 2019;14:4517-28. [PMID: 31354271 DOI: 10.2147/IJN.S199571] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
128 Srivastava S, Awasthi R, Tripathi D, Rai MK, Agarwal V, Agrawal V, Gajbhiye NS, Gupta RK. Magnetic-nanoparticle-doped carbogenic nanocomposite: an effective magnetic resonance/fluorescence multimodal imaging probe. Small 2012;8:1099-109. [PMID: 22328128 DOI: 10.1002/smll.201101863] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 4.5] [Reference Citation Analysis]
129 Wagner S, Schnorr J, Pilgrimm H, Hamm B, Taupitz M. Monomer-coated very small superparamagnetic iron oxide particles as contrast medium for magnetic resonance imaging: preclinical in vivo characterization. Invest Radiol 2002;37:167-77. [PMID: 11923639 DOI: 10.1097/00004424-200204000-00002] [Cited by in Crossref: 111] [Cited by in F6Publishing: 98] [Article Influence: 5.6] [Reference Citation Analysis]
130 Roca AG, Veintemillas-Verdaguer S, Port M, Robic C, Serna CJ, Morales MP. Effect of nanoparticle and aggregate size on the relaxometric properties of MR contrast agents based on high quality magnetite nanoparticles. J Phys Chem B 2009;113:7033-9. [PMID: 19378984 DOI: 10.1021/jp807820s] [Cited by in Crossref: 117] [Cited by in F6Publishing: 101] [Article Influence: 9.0] [Reference Citation Analysis]
131 Villaraza AJ, Bumb A, Brechbiel MW. Macromolecules, dendrimers, and nanomaterials in magnetic resonance imaging: the interplay between size, function, and pharmacokinetics. Chem Rev 2010;110:2921-59. [PMID: 20067234 DOI: 10.1021/cr900232t] [Cited by in Crossref: 466] [Cited by in F6Publishing: 408] [Article Influence: 38.8] [Reference Citation Analysis]
132 Allkemper T, Heindel W, Kooijman H, Ebert W, Tombach B. Effect of Field Strengths on Magnetic Resonance Angiography: Comparison of an Ultrasmall Superparamagnetic Iron Oxide Blood-Pool Contrast Agent and Gadopentetate Dimeglumine in Rabbits at 1.5 and 3.0 Tesla. Investigative Radiology 2006;41:97-104. [DOI: 10.1097/01.rli.0000194779.02079.ce] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
133 Pannu HK, Wang K, Borman TL, Bluemke DA. MR imaging of mediastinal lymph nodes: Evaluation using a superparamagnetic contrast agent. J Magn Reson Imaging 2000;12:899-904. [DOI: 10.1002/1522-2586(200012)12:6<899::aid-jmri13>3.0.co;2-r] [Cited by in Crossref: 49] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
134 Mallas G, Brooks DH, Rosenthal A, Nudelman RN, Mauskapf A, Jaffer FA, Ntziachristos V. Improving quantification of intravascular fluorescence imaging using structural information. Phys Med Biol 2012;57:6395-406. [PMID: 22996051 DOI: 10.1088/0031-9155/57/20/6395] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
135 Bremer C, Allkemper T, Baermig J, Reimer P. RES-specific imaging of the liver and spleen with iron oxide particles designed for blood pool MR-angiography. J Magn Reson Imaging 1999;10:461-7. [DOI: 10.1002/(sici)1522-2586(199909)10:3<461::aid-jmri30>3.0.co;2-5] [Cited by in Crossref: 27] [Article Influence: 1.2] [Reference Citation Analysis]
136 Arami H, Khandhar A, Liggitt D, Krishnan KM. In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles. Chem Soc Rev 2015;44:8576-607. [PMID: 26390044 DOI: 10.1039/c5cs00541h] [Cited by in Crossref: 405] [Cited by in F6Publishing: 133] [Article Influence: 57.9] [Reference Citation Analysis]
137 Tréhin R, Figueiredo JL, Pittet MJ, Weissleder R, Josephson L, Mahmood U. Fluorescent nanoparticle uptake for brain tumor visualization. Neoplasia 2006;8:302-11. [PMID: 16756722 DOI: 10.1593/neo.05751] [Cited by in Crossref: 70] [Cited by in F6Publishing: 59] [Article Influence: 4.4] [Reference Citation Analysis]
138 Serres S, Soto MS, Hamilton A, McAteer MA, Carbonell WS, Robson MD, Ansorge O, Khrapitchev A, Bristow C, Balathasan L, Weissensteiner T, Anthony DC, Choudhury RP, Muschel RJ, Sibson NR. Molecular MRI enables early and sensitive detection of brain metastases. Proc Natl Acad Sci U S A 2012;109:6674-9. [PMID: 22451897 DOI: 10.1073/pnas.1117412109] [Cited by in Crossref: 98] [Cited by in F6Publishing: 92] [Article Influence: 9.8] [Reference Citation Analysis]
139 Taupitz M, Schnorr J, Abramjuk C, Wagner S, Pilgrimm H, H�nigen H, Hamm B. New generation of monomer-stabilized very small superparamagnetic iron oxide particles (VSOP) as contrast medium for MR angiography: Preclinical results in rats and rabbits. J Magn Reson Imaging 2000;12:905-11. [DOI: 10.1002/1522-2586(200012)12:6<905::aid-jmri14>3.0.co;2-5] [Cited by in Crossref: 67] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]